Shares of Loxo Oncology Inc. (NASDAQ:LOXO) traded up 6.1% during trading on Thursday . The stock traded as high as $28.30 and last traded at $27.64, with a volume of 84,508 shares changing hands. The stock had previously closed at $26.04.

Several analysts have commented on the company. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Loxo Oncology in a research note on Tuesday, April 19th. Zacks Investment Research raised Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Thursday, May 5th. Cowen and Company reaffirmed a “buy” rating on shares of Loxo Oncology in a research note on Wednesday, July 13th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $36.00 price objective on shares of Loxo Oncology in a research note on Monday, April 18th. Five analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $29.60.

The firm’s market capitalization is $542.56 million. The stock has a 50-day moving average price of $24.57 and a 200 day moving average price of $23.25.

Loxo Oncology (NASDAQ:LOXO) last issued its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.14. On average, analysts anticipate that Loxo Oncology Inc. will post ($2.40) earnings per share for the current year.

In other Loxo Oncology news, major shareholder Aisling Capital Iii Lp acquired 232,558 shares of Loxo Oncology stock in a transaction dated Tuesday, May 17th. The stock was acquired at an average cost of $21.50 per share, for a total transaction of $4,999,997.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

An institutional investor recently bought a new position in Loxo Oncology stock. GSA Capital Partners LLP acquired a new stake in Loxo Oncology Inc. (NASDAQ:LOXO) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 37,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,055,000. GSA Capital Partners LLP owned about 0.22% of Loxo Oncology at the end of the most recent quarter.

Loxo Oncology, Inc is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer.